It’s not just a long life we’re striving for, but one which is worth living.

J. CRAIG VENTER, PHD
Co-Founder, Executive Chairman, Head of Scientific Strategy. Published the first human genome sequence in 2001.
Human Longevity, Inc. (HLI) is revolutionizing human health by generating and analyzing more genomic data for a deeper understanding into what can keep your patients living healthier longer. HLIQ Whole Genome provides insights into your patient’s personal risk for disease, information on how they may react to certain medications and those that might work better, as well as information on ancestry and personal traits.

Currently you see patients and initiate treatment when they present with symptoms and illness. HLIQ Whole Genome is a new tool to make healthcare more proactive, predictive and preventative by looking at the complete genome, not just a portion.
HLIQ Whole Genome is a comprehensive report that compares every letter of DNA with the world’s largest database of sequenced genomes and phenotype data, mined using HLI’s bioinformatic technology and analysis to study core building blocks that inform and impact health.

Our approach discovers genomic factors that potentially enable early detection of health risks or disease, identification of carrier status which is potentially helpful in reproductive decision-making, and potential adjustment of pharmacologic treatment to improve efficacy and/or reduce side effects—designed to support the care you provide.

HLIQ Whole Genome analysis report provides physicians and individuals a detailed exploration of the individual genome. Through comprehensive DNA sequencing and analysis, HLI brings unique information not found in other clinical screening tests. We can do this because we analyze individual genomes in the context of the tens of thousands of genomes in the HLI database, where more can be learned about one genome through its comparison with many.

While the ACMG 59 genes are what is clinically relevant currently, HLIQ Whole Genome puts your patients and their families in a position to be the first to benefit from new genomic-based information.

NEED HELP
clientservices@humanlongevity.com
Client Service Line: 844.838.3322
BE PART OF GROUNDBREAKING GENOMICS RESEARCH AND INVEST IN THE FUTURE OF MEDICINE

HLIQ Whole Genome Analyzes:

**CLINICAL**
ACMG 59
Carrier Status
Pharmacogenomics

**HEALTH INSIGHTS**
Cancer
Cardiovascular
Neurological
Respiratory
Metabolic and More

**PERSONAL INSIGHTS**
Ancestry
Allergy
Food Intolerances

**TRAITS**
Eye Color
Skin Color
Height
HOW HLIQ WHOLE GENOME MAY INFORM THE CARE OF MY PATIENTS

Personal and family health history is the foundation for assessment of your patient’s current health and of their risk for future health conditions. Adding HLIQ Whole Genome to this set of information has the potential to help you and your patients better inform their healthcare decisions.

HLIQ Whole Genome findings are contextualized using evidence-based medicine. The HLIQ Whole Genome sequences all of your patient’s DNA. The results are provided in two reports. The HLIQ Whole Genome Medically Significant Report (MSR) contains results from the most clinically useful, important, and scientifically validated findings. The contents of this report were selected because:

- They have been studied extensively by scientists;
- They are strongly linked to important diseases, health conditions or effects of medicines;
- Guidelines are available to provide clinical actionability for these risks, conditions and/or diseases;
- Medical tests and treatments are available which may be helpful to persons with these health risks or conditions.

NEED HELP
clientservices@humanlongevity.com
Client Service Line: 844.838.3322
The findings in the HLIQ Whole Genome MSR have been chosen not just for their association with the diseases, but also because medical action is possible. Medical action may include undergoing regular screening tests for cancer, taking medicine, changing certain lifestyle factors, or using other tests or treatments. These actions could protect your patient from harmful effects of the gene or gene variant, however, none of these actions can remove the harmful gene variant.

In addition to the MSR version of the HLIQ Whole Genome report, HLI provides a comprehensive and detailed version that includes genetic-based traits, ancestry, and other non-clinical information to your patient. We also provide you access to this longer report in case you would like to review the other genetic information provided to your patient.

It must be emphasized that while these reports will give accurate information about genetic variants and risk of the defined conditions associated with the HLIQ Whole Genome test, it cannot be used as a diagnostic test or to totally rule out a suspected condition.
Human Longevity, Inc. is the genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived. HLI combines the largest database of genomic and phenotypic data with machine learning to drive discoveries and revolutionize the practice of medicine. HLI’s business areas include the HLI Health Nucleus, a genomic powered clinical research center which uses whole genome sequence analysis, advanced clinical imaging and innovative machine learning, along with curated personal health information, to deliver the most complete picture of individual health; HLIQ Whole Genome and HLIQ Oncology. For more information, please visit humanlongevity.com or healthnucleus.com.